Key Takeaways from the Interstitial Cystitis Market Report<\/p>\n
According to DelveInsight’s analysis, the market size for interstitial cystitis\u00a0was found to be USD 3 billion in the 7MM in 2024.
\n The United States accounted for the highest market size of interstitial cystitis, approximately 75% of the total market size in 7MM in 2024, in comparison to the other major markets, i.e., EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
\n In 2024, the prevalent cases of interstitial cystitis were approximately 11 million across the 7MM, reflecting its significant disease burden and the pressing need for improved diagnostic tools and more effective treatments.
\n Leading interstitial cystitis\u00a0companies developing emerging therapies, such as Vaneltix Pharma, Hyloris Pharma, Ono Pharmaceutical, Seikagaku Corporation, Imbrium Therapeutics, ASKA Pharmaceutical, and others, are developing novel interstitial cystitis drugs that can be available in the interstitial cystitis market in the coming years.
\n The promising interstitial cystitis\u00a0therapies in the pipeline include ALENURA (Lidocaine + Heparin), ONO-1110, SI-722, Sunobinop (V117957), AKP-021, and others.
\n In March 2025, Hyloris announced a positive interim review outcome for the ALENURA clinical trial, with the IDMC recommending its continuation. Patient enrollment is expected to be completed by the end of 2025. ALENURA is being developed as a potential first-line treatment for interstitial cystitis.<\/p>\n
Discover which therapies are expected to grab the major interstitial cystitis drugs market share @ Interstitial Cystitis Market Report<\/a><\/p>\n Interstitial Cystitis Overview<\/p>\n Interstitial cystitis, also known as bladder pain syndrome, is a chronic condition characterized by persistent bladder pressure, pain, and sometimes pelvic discomfort. The exact cause of interstitial cystitis is not fully understood, but several factors are believed to contribute, including defects in the bladder lining, autoimmune responses, nerve hypersensitivity, or chronic inflammation. It is more common in women and may be associated with other chronic pain syndromes such as irritable bowel syndrome or fibromyalgia.<\/p>\n The primary symptoms of interstitial cystitis include a frequent and urgent need to urinate, pelvic pain that worsens as the bladder fills, and relief of discomfort after urination. Pain may range from mild to severe and can radiate to the lower back, urethra, or abdomen. Unlike typical urinary tract infections, interstitial cystitis does not usually involve bacterial infection, and antibiotics are ineffective in treating it.<\/p>\n Diagnosis of interstitial cystitis can be challenging as its symptoms often overlap with other urinary conditions. Physicians typically rely on patient history, physical examinations, and symptom assessment. Tests such as urinalysis, urine cultures, cystoscopy, or urodynamic studies may be performed to rule out other causes like infections, kidney stones, or bladder cancer. Since there is no definitive test for interstitial cystitis, it is often diagnosed through exclusion of other conditions.<\/p>\n Interstitial Cystitis Epidemiology Segmentation<\/p>\n The interstitial cystitis\u00a0epidemiology section provides insights into the historical and current interstitial cystitis\u00a0patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.<\/p>\n The interstitial cystitis\u00a0market report\u00a0proffers epidemiological analysis for the study period 2020\u20132034 in the 7MM segmented into:<\/p>\n Prevalent Cases of Interstitial Cystitis Interstitial Cystitis Treatment Market<\/p>\n For most patients, there is no single treatment that can cure interstitial cystitis or provide permanent relief from its symptoms. Optimal symptom management often requires a combination of multiple therapies, and patients should understand that the condition is chronic, characterized by alternating periods of flare-ups and remission.<\/p>\n The initial approach to treatment typically focuses on dietary and lifestyle changes. Dietary adjustments are guided by common irritants, while elimination diets help identify additional personal triggers. A personalized diet plan is essential, with patients encouraged to maintain a diary to track foods, beverages, additives, or substances that aggravate their symptoms. Surgical intervention is now less common due to the effectiveness of intradetrusor botulinum toxin A injections, but it remains a last-resort option for severe cases. Open surgery can provide pain relief in the majority of patients, while urethrectomy is rarely performed due to its significant risks and complexity.<\/p>\n Currently, only two treatments have been approved for interstitial cystitis: ELMIRON (Johnson & Johnson) and ZYMSO (Kyorin Pharmaceuticals), an intravesical therapy approved in Japan. This limited availability highlights the pressing need for more effective and widely accessible therapeutic options.<\/p>\n ELMIRON is a semi-synthetic, heparin-like macromolecular carbohydrate derivative that closely resembles glycosaminoglycans in its chemical structure. It is a white, odorless, slightly hygroscopic powder that is water-soluble (up to 50% at pH 6). The drug is available as white, opaque hard gelatin capsules, each containing 100 mg of pentosan polysulfate sodium, microcrystalline cellulose, and magnesium stearate, formulated for oral administration. In June 2017, ELMIRON received marketing authorization from the European Commission, approving use across the European Union for the treatment of interstitial cystitis.<\/p>\n ZYMSO is an intravesical solution composed of 50% dimethyl sulfoxide (DMSO). It offers a targeted, non-systemic treatment option for patients with refractory Hunner-type interstitial cystitis. By delivering high concentrations of DMSO directly into the bladder, ZYMSO provides potent local anti-inflammatory and analgesic effects with a well-established safety profile. In January 2021, Kyorin Pharmaceutical obtained marketing authorization from Japan’s Ministry of Health, Labour and Welfare (MHLW) for ZYMSO Intravesical Solution 50% as a treatment for interstitial cystitis.<\/p>\n To know more about the interstitial cystitis drug market, visit @ Interstitial Cystitis Treatment Options<\/a><\/p>\n Interstitial Cystitis Pipeline Therapies and Key Companies<\/p>\n ALENURA (Lidocaine + Heparin): Vaneltix Pharma\/Hyloris Pharma Discover more about interstitial cystitis medication\u00a0@ Interstitial Cystitis Clinical Trials<\/a><\/p>\n Interstitial Cystitis Market Dynamics<\/p>\n The interstitial cystitis\u00a0market dynamics are expected to change in the coming years. People with interstitial cystitis have access to various treatments, including dietary changes, medications, bladder instillations, and physical therapy, while the therapeutic pipeline appears robust with multiple investigational agents in development; the global interstitial cystitis market is projected to grow due to rising demand for effective diagnostics and therapeutics, and emerging options like gentle shock wave therapy, botulinum toxin injections, and regenerative approaches are offering new hope for patients.<\/p>\n Furthermore, potential therapies are being investigated for the treatment of interstitial cystitis, and it is safe to predict that the treatment space will significantly impact the interstitial cystitis\u00a0market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the interstitial cystitis\u00a0market in the 7MM.<\/p>\n However, several factors may impede the growth of the interstitial cystitis\u00a0market. Interstitial cystitis is often misdiagnosed as other urologic or gynecologic conditions, such as urinary tract infections or overactive bladder, leading to significant delays in treatment and increasing patient burden, healthcare costs, and frustration due to the trial-and-error approach required, as no single treatment works for all; with few FDA-approved drugs (e.g., pentosan polysulfate sodium, which has safety concerns) and most treatments being off-label, these challenges can potentially undermine trust in the healthcare system and hinder timely market adoption of targeted interstitial cystitis therapies.<\/p>\n Moreover, interstitial cystitis\u00a0treatment poses a significant economic burden and disrupts patients’ overall well-being and QOL. Furthermore, the interstitial cystitis market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the interstitial cystitis market growth.<\/p>\n Interstitial Cystitis Market Report Metrics<\/p>\n Details<\/p>\n Study Period<\/p>\n 2020\u20132034<\/p>\n Coverage<\/p>\n 7MM [The United States, the EU4 (Germany, France, Italy, and Spain) and The United Kingdom, and Japan].<\/p>\n Interstitial Cystitis Market CAGR<\/p>\n 4\u00a0%<\/p>\n Interstitial Cystitis Market Size in 2024<\/p>\n USD 3 Billion<\/p>\n Key Interstitial Cystitis Companies<\/p>\n Vaneltix Pharma, Hyloris Pharma, Ono Pharmaceutical, Seikagaku Corporation, Imbrium Therapeutics, ASKA Pharmaceutical, Johnson & Johnson, KYORIN Pharmaceuticals, and others<\/p>\n Key Interstitial Cystitis Therapies<\/p>\n ALENURA (Lidocaine + Heparin), ONO-1110, SI-722, Sunobinop (V117957), AKP-021, ELMIRON, ZYMSO, and others<\/p>\n Scope of the Interstitial Cystitis\u00a0Market Report<\/p>\n Therapeutic Assessment: Interstitial Cystitis\u00a0current marketed and emerging therapies Download the report to understand more about the drugs to treat interstitial cystitis\u00a0@\u00a0New Treatments for Interstitial Cystitis<\/a><\/p>\n Table of Contents<\/p>\n 1<\/p>\n Key Insights<\/p>\n 2<\/p>\n Report Introduction<\/p>\n 3<\/p>\n Interstitial Cystitis Market Overview at a Glance<\/p>\n 3.1<\/p>\n Market Share (%) Distribution of Interstitial Cystitis by Country in 2024 in the 7MM<\/p>\n 3.2<\/p>\n Market Share (%) Distribution of Interstitial Cystitis by Country in 2034 in the 7MM<\/p>\n 4<\/p>\n Epidemiology and Market Methodology<\/p>\n 5<\/p>\n Executive Summary<\/p>\n 6<\/p>\n Key Events<\/p>\n 7<\/p>\n Disease Background and Overview<\/p>\n 7.1<\/p>\n Introduction<\/p>\n 7.2<\/p>\n Classification of Interstitial Cystitis<\/p>\n 7.3<\/p>\n Signs and Symptoms<\/p>\n 7.4<\/p>\n Risk Factors and Causes<\/p>\n 7.5<\/p>\n Pathophysiology of Interstitial Cystitis<\/p>\n 7.6<\/p>\n Complications<\/p>\n 7.7<\/p>\n Diagnosis<\/p>\n 7.7.1<\/p>\n Diagnostic Guidelines<\/p>\n 7.7.2<\/p>\n Differential Diagnosis (DDx)<\/p>\n 8<\/p>\n Treatment and Management<\/p>\n 8.1<\/p>\n Treatment Guidelines<\/p>\n 8.1.1<\/p>\n AUA Guidelines (2022)<\/p>\n 8.1.2<\/p>\n EAU Guidelines on Chronic Pelvic Pain (2025)<\/p>\n 8.1.3<\/p>\n UK: British Society of Urogynaecology (BSUG) Green-top Guidelines for BPS (2016)<\/p>\n 8.1.4<\/p>\n Germany: S2K guideline for the Treatment of Interstitial Cystitis (2018)<\/p>\n 8.1.5<\/p>\n Japan Urological Association (JUA) Clinical Guidelines for Interstitial Cystitis\/BPS (2020)<\/p>\n 8.2<\/p>\n Diagnosis and Treatment Algorithm<\/p>\n 9<\/p>\n Epidemiology and Patient Population<\/p>\n 9.1<\/p>\n Key Findings<\/p>\n 9.2<\/p>\n Assumptions and Rationale<\/p>\n 9.3<\/p>\n Total Diagnosed Prevalent Cases of Interstitial Cystitis in the 7MM<\/p>\n 9.4<\/p>\n The United States<\/p>\n 9.4.1<\/p>\n Prevalent Cases of Interstitial Cystitis in the United States<\/p>\n 9.4.2<\/p>\n Total Diagnosed Prevalent Cases of Interstitial Cystitis in the United States<\/p>\n 9.4.3<\/p>\n Age-specific Cases of Interstitial Cystitis in the United States<\/p>\n 9.4.4<\/p>\n Gender-specific Cases of Interstitial Cystitis in the United States<\/p>\n 9.4.5<\/p>\n Severity-specific Cases of Interstitial Cystitis in the United States<\/p>\n 9.4.6<\/p>\n Type-specific Cases of Interstitial Cystitis in the United States<\/p>\n 9.4.7<\/p>\n Total Treated Cases of Interstitial Cystitis in the United States<\/p>\n 9.5<\/p>\n EU4 and the UK<\/p>\n 9.6<\/p>\n Japan<\/p>\n 10<\/p>\n Patient Journey<\/p>\n 11<\/p>\n Marketed Therapies<\/p>\n 11.1<\/p>\n Key Cross Competition<\/p>\n 11.2<\/p>\n ELMIRON (pentosan polysulfate sodium): Johnson & Johnson<\/p>\n 11.2.1<\/p>\n Product Description<\/p>\n 11.2.2<\/p>\n Regulatory Milestones<\/p>\n 11.2.3<\/p>\n Other Developmental Activities<\/p>\n 11.2.4<\/p>\n Safety and efficacy<\/p>\n 11.3<\/p>\n ZYMSO (Dimethyl Sulfoxide): KYORIN Pharmaceuticals<\/p>\n 12<\/p>\n Emerging Therapies<\/p>\n 12.1<\/p>\n Key Cross Competition<\/p>\n 12.2<\/p>\n ALENURA (lidocaine + heparin): Vaneltix Pharma\/Hyloris Pharma<\/p>\n 12.2.1<\/p>\n Product Description<\/p>\n 12.2.2<\/p>\n Other Developmental Activities<\/p>\n 12.2.3<\/p>\n Clinical Development<\/p>\n 12.2.4<\/p>\n Safety and Efficacy<\/p>\n 12.2.5<\/p>\n Analyst View<\/p>\n 13<\/p>\n Interstitial Cystitis – Seven Major Market Analysis<\/p>\n 13.1<\/p>\n Key Findings<\/p>\n 13.2<\/p>\n Market Outlook<\/p>\n 13.3<\/p>\n Key Market Forecast Assumptions<\/p>\n 13.4<\/p>\n Total Market Size of Interstitial Cystitis in the 7MM<\/p>\n 13.5<\/p>\n Market Size of Interstitial Cystitis by Therapies in the 7MM<\/p>\n 13.6<\/p>\n Market Size in the United States<\/p>\n 13.7<\/p>\n Market Size in EU4 and the UK<\/p>\n 13.8<\/p>\n Market Size in Japan<\/p>\n 14<\/p>\n KOL Views<\/p>\n 15<\/p>\n SWOT Analysis<\/p>\n 16<\/p>\n Unmet Needs<\/p>\n 17<\/p>\n Market Access and Reimbursement<\/p>\n 17.1<\/p>\n United States<\/p>\n 17.2<\/p>\n EU4 and the UK<\/p>\n 17.3<\/p>\n Japan<\/p>\n 17.4<\/p>\n Reimbursement Scenario in Interstitial Cystitis<\/p>\n 18<\/p>\n Bibliography<\/p>\n 19<\/p>\n Report Methodology<\/p>\n Related Reports<\/p>\n Interstitial Cystitis Pipeline<\/a><\/p>\n Interstitial Cystitis\u00a0Pipeline Insight \u2013\u00a02025\u00a0report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key interstitial cystitis\u00a0companies, including Merck & Co., Teva Pharmaceutical Industries, Integrative Therapeutics, Inc., Lipella Pharmaceuticals, Inc., Addex Therapeutics, Seikagaku Corporation, UCB, Alivio Therapeutics, Imbrium Therapeutics, Ironwood Pharmaceuticals, among others.<\/p>\n Cystitis\u00a0Market<\/a><\/p>\n Cystitis\u00a0Market Insights, Epidemiology, and Market Forecast \u2013 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key cystitis\u00a0companies, including Abeona Therapeutics, Castle Creek Biosciences, RHEACELL, Ishin Pharma, Holostem Terapie Avanzate, BridgeBio (Phoenix Tissue Repair), InMed Pharmaceuticals, Shionogi, Anterogen, among others.<\/p>\n Cystitis\u00a0Pipeline<\/a><\/p>\n Cystitis\u00a0Pipeline Insight \u2013\u00a02025\u00a0report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key cystitis\u00a0companies, including Seikagaku Corporation, Lipella Pharmaceuticals, AlloVir, Ironwood Pharmaceuticals, Paratek Pharmaceuticals, Alivio Therapeutics, Vaneltix Pharma, Qu Biologics, Imbrium Therapeutics, MIRAE CELL BIO, among others.<\/p>\n Fibromyalgia\u00a0Market<\/a><\/p>\n Fibromyalgia\u00a0Market Insights, Epidemiology, and Market Forecast \u2013 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key fibromyalgia\u00a0companies, including Eli Lilly and Company, Pfizer, Virios Therapeutics, Novartis AG, Allergan plc, Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Intec Pharma Ltd., Aptinyx, Prismic Pharmaceuticals, Astellas Pharma Inc., among others.<\/p>\n About\u00a0DelveInsight<\/p>\n DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.\u00a0Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform\u00a0PharmDelve.<\/p>\n Contact Us
\n Total Diagnosed Prevalent Cases of Interstitial Cystitis
\n Age-specific Cases of Interstitial Cystitis
\n Gender-specific Cases of Interstitial Cystitis
\n Severity-specific Cases of Interstitial Cystitis
\n Type-specific Cases of Interstitial Cystitis
\n Total Treated Cases of Interstitial Cystitis<\/p>\n
\n ONO-1110: Ono Pharmaceutical
\n SI-722: Seikagaku Corporation
\n Sunobinop (V117957): Imbrium Therapeutics
\n AKP-021: ASKA Pharmaceutical<\/p>\n
\n Interstitial Cystitis\u00a0Market Dynamics:\u00a0Key Market Forecast Assumptions of Emerging Interstitial Cystitis\u00a0Drugs and Market Outlook
\n Competitive Intelligence Analysis:\u00a0SWOT analysis and Market entry strategies
\n Unmet Needs, KOL’s views, Analyst’s views, Interstitial Cystitis Market Access and Reimbursement<\/p>\n
Shruti Thakur
[email\u00a0protected]<\/a>
+14699457679
www.delveinsight.com<\/a><\/p>\n
![\"\"](\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=IO43319&Transmission_Id=202508041731PR_NEWS_USPR_____IO43319&DateId=20250804\")
<\/p>\n","protected":false},"excerpt":{"rendered":"The interstitial cystitis market is limited by a few approved treatments and high unmet need. However, pipeline innovation…\n","protected":false},"author":2,"featured_media":44219,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12],"tags":[84,9459,9460,467,56,54,55],"class_list":{"0":"post-44218","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-markets","8":"tag-business","9":"tag-delveinsight-business-research","10":"tag-llp","11":"tag-markets","12":"tag-uk","13":"tag-united-kingdom","14":"tag-unitedkingdom"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/44218","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/comments?post=44218"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/44218\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media\/44219"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media?parent=44218"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/categories?post=44218"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/tags?post=44218"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}